GleamWall
中文EN

ALT Altimmune, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%

Returns

ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$26,000$5,000$5,000$5,000$5,000
R&D expense$27.02M$18.66M$16.19M$18.41M$14.96M$17.24M$15.83M$19.78M
SG&A expense$8.69M$7.57M$8.05M$10.51M$5.90M$5.69M$5.99M$5.09M
Operating income-$35.70M-$26.23M-$24.24M-$28.89M-$20.86M-$22.92M-$21.82M-$24.87M
Interest expense$1.12M$1.10M$1.07M$876,000$495,000$264,000$1,000$1,000
Pretax income-$31.61M-$22.82M-$22.56M-$27.36M-$19.01M-$22.15M-$20.26M-$23.18M
Income tax———$0$0$0-$681,000—
Net income-$31.61M-$22.82M-$22.56M-$27.36M-$19.01M-$22.15M-$19.57M-$23.18M
EBITDA-$35.69M-$26.21M-$24.22M-$28.87M-$20.83M-$22.89M-$21.79M-$24.83M
EPS (basic)-0.15-0.12-0.18—-0.21-0.27-0.26—
EPS (diluted)-0.15-0.12-0.18—-0.21-0.27-0.26—
Weighted avg. shares (diluted)205.27M185.44M124.46M—89.42M81.48M75.55M—
Balance sheet
Cash & equivalents$28.89M$63.01M$97.60M$43.76M$61.28M$183.15M$49.15M$36.97M
Short-term investments$236.17M$263.27M$233.94M$229.70M$149.54M—$100.72M$94.97M
Current assets$275.77M$334.81M$334.68M$278.19M$216.62M$188.42M$155.26M$137.25M
PP&E, net$112,000$60,000$208,000$312,000$337,000$364,000$384,000$413,000
Intangibles———————$0
Total assets$495.65M$527.21M$335.63M$279.93M$218.45M$190.35M$157.26M$139.31M
Current liabilities$11.53M$12.50M$11.32M$15.00M$12.61M$9.22M$9.80M$10.47M
Long-term debt$34.99M$34.74M$34.51M$34.29M$14.45M$14.33M——
Total debt$34.99M$34.74M$34.51M$34.29M$14.45M$14.33M——
Total liabilities$52.08M$53.00M$51.64M$55.04M$32.85M$28.98M$15.10M$15.80M
Shareholders' equity$443.57M$474.21M$283.99M$224.89M$185.60M$161.37M$142.16M$123.51M
Net debt$6.10M-$28.27M-$63.10M-$9.47M-$46.83M-$168.81M——
Shares outstanding194.54M194.47M130.22M110.88M95.60M85.08M77.83M72.35M
Cash flow statement
Operating cash flow-$37.74M-$24.22M-$20.94M-$19.45M-$11.90M-$19.35M-$16.84M-$18.27M
Capital expenditure$64,000$32,000$21,000$1,000$0———
Free cash flow-$37.81M-$24.25M-$20.96M-$19.45M-$11.90M———
Investing cash flow$3.54M-$221.44M-$3.69M-$79.16M-$149.32M$101.11M-$5.10M$13.63M
Financing cash flow$82,000$211.07M$78.47M$81.13M$39.35M$52.24M$34.12M$10.09M
Depreciation & amortization$11,000$23,000$23,000$26,000$27,000$30,000$29,000$33,000
Stock-based compensation$2.87M$2.79M$3.38M$4.94M$3.55M$3.57M$4.01M$3.35M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.